MabThera (Rituximab) nu som subkutan
-
Roche opnår gennembrud med kræftmiddel
Med en ny behandlingsmetode opnår et allerede eksisterende kræftmiddel store fordele i behandlingen af lymfeknudekræft.
(medwatch.dk)
Midt i al nyhedsstrømmen om Genmabs fremdrift med sin kliniske udvikling er det værd at bewmærke at heller ikke konkurrenten ligger på den lade side.
Nu med den subcutane løsning.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind